Up next

Autoplay

Defining Progression in Metastatic Kidney Cancer

3 Views • 06/26/23
Share
Embed
administrator
administrator
Subscribers
0

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay